FDA Issues Emergency Use Authorization for Impella RP as Therapy for COVID-19 Patients with Right Heart Failure

Acute Coronary Syndromes (ACS) Cardio-oncology CHIP/Complex PCI CTO Heart Failure Hemodynamic Support Hypertrophic Cardiomyopathy Left Main Bifurcation SIHD

The United States Food and Drug Administration has issued an emergency use authorization for Impella RP to include patients suffering from COVID-19 related right heart failure or decompensation, including pulmonary embolism.

From Cath Lab Digest

Read Article—Cath Lab Digest

Other Specialist Resources for Coronary Heart Disease

Including recently published studies, coverage of late-breaking science, updates from clinical trials and registries, and complex case presentations.

Clinical Interest Article

Lipoprotein(a) Identifies Residual Cardiovascular Risk in NIH Randomized Trials—Coverage of SCAI Scientific Sessions 2026

Clinical Interest Article

Can Escalation Reduce Acute Myocardial Infarction Mortality in Cardiogenic Shock (CERAMICS)—Coverage of SCAI Scientific Sessions 2026

Clinical Interest Article

Sirolimus Eluting Balloons for Patients with Acute Coronary Syndrome: Evidence from the SELUTION Denovo Trial—Coverage of SCAI Scientific Sessions 2026

Clinical Interest Article

ORBITA-CTO: A Randomized, Placebo-Controlled Trial of Chronic Total Occlusion Percutaneous Coronary Intervention in Stable Angina—Coverage of ACC 2026

Clinical Interest Article

DKCRUSH VIII: IVUS or Angiography Guidance for PCI in Complex Coronary Bifurcation Lesions—Coverage of ACC 2026

Clinical Interest Article

HOST-EXAM Trial 10-Year Follow Up: Aspirin vs. Clopidogrel for Chronic Maintenance Monotherapy After Percutaneous Coronary Intervention—Coverage of ACC 2026

SCAI^® is a registered trademark of the Society for Cardiovascular Angiography & Interventions.

All content found on the Society for Cardiovascular Angiography & Interventions website (www.scai.org) including text, images, audio, video, or other formats is created for informational purposes only. Links to other content are to be taken at your own risk. SCAI is not responsible for the content or claims of external websites.

Connect